H

Herantis Pharma Oyj
OMXH:HRTIS

Watchlist Manager
Herantis Pharma Oyj
OMXH:HRTIS
Watchlist
Price: 1.555 EUR -5.76% Market Closed
Market Cap: 31.3m EUR
Have any thoughts about
Herantis Pharma Oyj?
Write Note

Herantis Pharma Oyj
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Herantis Pharma Oyj
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
H
Herantis Pharma Oyj
OMXH:HRTIS
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Orion Oyj
OMXH:ORNBV
Gross Profit
€707.9m
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
1%
No Stocks Found

Herantis Pharma Oyj
Glance View

Market Cap
31.3m EUR
Industry
Pharmaceuticals

Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. The company is headquartered in Espoo, Etela-Suomen. The company went IPO on 2014-06-11. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.

HRTIS Intrinsic Value
0.172 EUR
Overvaluation 89%
Intrinsic Value
Price
H

See Also

Back to Top